Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8032116 | 0.84 | CTSS (0.34) | ALDH1A1SMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL13062479 | 0.71 | NPSR1 (0.47) | ALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL14919735 | 0.62 | GAA (0.33) | SMN1; SMN2 | |
| SCHEMBL14919734 | 0.62 | GAA (0.33) | SMN1; SMN2 | |
| SCHEMBL22495730 | 0.61 | S100B (0.39) | ALDH1A1KDM4EHPGDSMN1; SMN2MEN1 | |
| SCHEMBL17170062 | 0.59 | CYP3A4 (0.47) | TSHR | |
| SCHEMBL10527322 | 0.59 | SIGMAR1 (0.64) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL10527317 | 0.59 | SIGMAR1 (0.64) | ALDH1A1HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL506923 | 0.58 | SMN1; SMN2 (0.46) | ALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL17192830 | 0.57 | KMT2A (0.42) | ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | ALDH1A1 1718/4885KDM4E 1399/4885HPGD 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.